Study Comparing Izalontamab Brengitecan to Platinum-based Chemotherapy for Advanced Urothelial Cancer After Immunotherapy

Inclusion Criteria

• Have a confirmed diagnosis of advanced urothelial cancer.
• Be eligible to receive platinum-based chemotherapy.
• Have previously received immunotherapy for advanced or metastatic cancer, either alone or with other treatments.
• If treated with immunotherapy around the time of surgery, the cancer must have returned within 12 months after the last treatment.
• Have at least one tumor that can be measured by scans.
• Be in good overall health, with a performance status score of 0 or 1, meaning fully active or restricted in physically strenuous activity but ambulatory.

Exclusion Criteria

• Have not received platinum-based chemotherapy in the past 12 months.
• Have not had more than two previous treatment regimens, regardless of the setting.
• Have not received previous treatments targeting EGFR or HER3.
• Have not been treated with topoisomerase 1 inhibitors before.
• Do not have active, untreated cancer that has spread to the brain.
• Other specific criteria may apply.